NCT02569567

Brief Summary

The aim of this prospective study was to evaluate the applicability and diagnostic performances of Smart-Shear wave(SSW) imaging, in comparison with Transient elastography(TE) for the staging of liver fibrosis using pathologic results as the reference standard.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
105

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2015

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 5, 2015

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 7, 2015

Completed
25 days until next milestone

Study Start

First participant enrolled

November 1, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

November 17, 2015

Status Verified

October 1, 2015

Enrollment Period

7 months

First QC Date

October 5, 2015

Last Update Submit

November 14, 2015

Conditions

Keywords

Smart-Shear Wave(SSW)Transient Elastography(TE)Liver cirrhosis

Outcome Measures

Primary Outcomes (1)

  • Non-inferiority of Smart-Shear Wave(SSW) imaging compared to Transient elastography(TE) in diagnosis for hepatic fibrosis.

    Applicability rate between Smart-Shear Wave(SSW) and Transient elastography(TE) will be compared to prove non-inferiority. Applicability rate = {\[Total cases- (failure cases + non-reliable measurement cases)\]/total case} \* 100 (%)

    1 year

Secondary Outcomes (4)

  • Evaluation of diagnostic accuracy to predict the degree of hepatic fibrosis.

    1 year

  • The correlation between two US elastography techniques

    1 year

  • Reliability of Smart-Shear Wave(SSW) comparing diagnostic performance according to the reliable measurement index(RMI) results

    1 year

  • Precision of Smart-Shear Wave(SSW)

    1 year

Study Arms (1)

US elastography

Participants who have the plan of liver transplantation or liver biopsy within 4 weeks will be screened from the outpatient clinic. Two types of ultrasonographic elastography(US elastography) techniques including Smart-Shear Wave(SSW) imaging and transient elastography(TE) will be performed as a diagnostic method for hepatic fibrosis.

Procedure: Smart-Shear Wave(SSW) imagingProcedure: Transient elastography(TE)

Interventions

1. All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator. 2. The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction. 3. Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement.

Also known as: S-Shearwave
US elastography

1. Using the M probe in patients with BMI \<30 kg/m2. 2. Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface. 3. Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results.

Also known as: FibroScan®
US elastography

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A total of 105 participants will be enrolled. Participants are patients with liver disease who are planning to undergo liver surgery, and potential liver donors for living related liver transplantation. Study population size was calculated by considering a power of 80%(1-sided alpha of 25%), and an expected dropout rate of 10%.

You may qualify if:

  • Patients with liver disease: plan to undergo liver surgery
  • Potential liver donors
  • Smart-Shear wave \& transient elastography were performed within one month from liver surgery
  • Aged between 20 to 80 years
  • Compliance with scheduled visits, evaluation plans and other study procedures

You may not qualify if:

  • Previous history of hepatic surgery
  • Previous history of transarterial chemoembolization
  • Huge or infiltrative tumor in the right lobe of the liver
  • Bile duct dilatation in the right lobe of the liver
  • Older than 80 years
  • The opinion of the investigator would make the patient unsuitable for enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asan Medical Center

Seoul, 05505, South Korea

RECRUITING

MeSH Terms

Conditions

Liver Cirrhosis

Interventions

X-Rays

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Electromagnetic RadiationElectromagnetic PhenomenaMagnetic PhenomenaPhysical PhenomenaRadiationRadiation, Ionizing

Study Officials

  • So Yeon Kim, Dr

    Asan Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

October 5, 2015

First Posted

October 7, 2015

Study Start

November 1, 2015

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

November 17, 2015

Record last verified: 2015-10

Locations